Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Eterna Therapeutics Inc (ERNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: ERNA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -72.52% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.62M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) - | Beta 7.12 | 52 Weeks Range 1.75 - 39.45 | Updated Date 06/29/2025 |
52 Weeks Range 1.75 - 39.45 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -32.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2652.9% |
Management Effectiveness
Return on Assets (TTM) -32.42% | Return on Equity (TTM) -2264.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14647264 | Price to Sales(TTM) 25.45 |
Enterprise Value 14647264 | Price to Sales(TTM) 25.45 | ||
Enterprise Value to Revenue 27.38 | Enterprise Value to EBITDA -0.29 | Shares Outstanding 7361200 | Shares Floating 1664157 |
Shares Outstanding 7361200 | Shares Floating 1664157 | ||
Percent Insiders 61.04 | Percent Institutions 1.35 |
Upturn AI SWOT
Eterna Therapeutics Inc
Company Overview
History and Background
Eterna Therapeutics Inc. was founded in 2020 with the goal of revolutionizing cancer treatment through proprietary RNA-based therapies. The company focuses on developing novel mRNA therapeutics to address unmet medical needs in oncology. Significant milestones include the establishment of its core technology platform and early-stage research advancements.
Core Business Areas
- RNA-Based Therapeutics: Development of novel mRNA therapeutics for cancer treatment. This includes personalized cancer vaccines and in-vivo generated therapeutic proteins.
Leadership and Structure
Eterna Therapeutics Inc. is led by a management team with expertise in biotechnology and drug development. The company operates with a research-focused structure, emphasizing scientific innovation and clinical development.
Top Products and Market Share
Key Offerings
- mRNA Cancer Vaccines: Eterna is developing personalized mRNA cancer vaccines designed to stimulate an immune response against specific tumor antigens. The current market share for mRNA cancer vaccines is nascent, with limited approved products. Key competitors include Moderna and BioNTech, who are also actively developing cancer vaccines.
- In-vivo Therapeutic Protein Generation: This platform aims to enable the body to produce therapeutic proteins directly, addressing various disease states. This is an emerging area with significant potential, and direct market share data is not yet available. Competitors in the broader protein therapy space include companies like Amgen and Pfizer.
Market Dynamics
Industry Overview
The biotechnology sector, particularly in oncology, is characterized by rapid innovation, significant investment, and a high degree of scientific risk. The mRNA therapeutic space is rapidly evolving, with increasing interest from pharmaceutical companies and research institutions.
Positioning
Eterna Therapeutics Inc. is positioning itself as a leader in the development of novel RNA-based oncology treatments. Its competitive advantage lies in its proprietary mRNA platform and its focus on personalized medicine approaches.
Total Addressable Market (TAM)
The TAM for oncology therapeutics is vast, estimated in the hundreds of billions of dollars globally. Eterna's TAM is specifically within the cancer vaccine and novel protein therapy segments, which are projected to grow substantially. The company is aiming to capture a significant share of these specialized markets as its pipeline matures.
Upturn SWOT Analysis
Strengths
- Proprietary RNA-based therapeutic platform
- Focus on personalized cancer vaccines
- Experienced leadership team
- Potential for novel therapeutic protein generation
Weaknesses
- Early-stage company with limited clinical data
- High R&D costs and long development timelines
- Dependence on future funding
- Unproven long-term efficacy and safety of its novel platforms
Opportunities
- Growing demand for innovative cancer treatments
- Advancements in gene editing and delivery technologies
- Potential for strategic partnerships with larger pharmaceutical companies
- Expansion into other therapeutic areas beyond oncology
Threats
- Intense competition in the oncology drug market
- Regulatory hurdles and lengthy approval processes
- Emergence of competing technologies
- Unforeseen clinical trial failures
- Economic downturns impacting R&D investment
Competitors and Market Share
Key Competitors
- Moderna Inc. (MRNA)
- BioNTech SE (BNTX)
- Arcturus Therapeutics Holdings Inc. (ARCT)
Competitive Landscape
Eterna's competitive landscape is highly dynamic. While it possesses a novel platform, it faces established players with advanced clinical pipelines and significant capital. Its success will depend on differentiating its therapeutic approach and demonstrating superior efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: Eterna Therapeutics Inc. has experienced growth in its research capabilities, team size, and pipeline development since its inception.
Future Projections: Future projections are highly speculative and depend on successful clinical trial outcomes and market adoption of its therapies. Analyst estimates are not yet widely available for this early-stage company.
Recent Initiatives: Recent initiatives likely focus on advancing preclinical studies, optimizing its RNA platform, and potentially initiating early-stage human trials.
Summary
Eterna Therapeutics Inc. is an early-stage biotechnology company with a promising RNA-based platform for oncology. Its strengths lie in its innovative technology and focus on personalized medicine. However, it faces significant challenges including high R&D costs, long development timelines, intense competition, and regulatory hurdles. The company needs to demonstrate clinical success and secure substantial funding to navigate these threats and realize its potential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry research reports
- Financial news outlets
- Biotechnology databases
Disclaimers:
This JSON output is generated for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any securities. The information provided is based on publicly available data and may not be exhaustive or completely accurate. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eterna Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 1992-10-19 | CEO, President & Director Mr. Sanjeev Luther | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.ernexatx.com |
Full time employees 6 | Website https://www.ernexatx.com | ||
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.